Inclusion criteria were patients with acromegaly aged 18–75 years who had been treated with injectable SRLs for at least 6 months prior (on a stable dose ≥4 months) with biochemical control (mean IGF-1<1.3 ULN and mean integrated GH<2.5 ng/mL at screening). Here, GH1 is linked to acromegaly.